Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

COMMD8 Inhibitors

COMMD8 inhibitors constitute a distinctive and specialized chemical class meticulously designed to exert influence over the intricate functions of the COMMD8 protein. The acronym COMMD8stands for Copper Metabolism MURR1 Domain 8,denoting its involvement in multifaceted cellular processes such as copper homeostasis, intracellular protein trafficking, and the modulation of the NF-κB signaling pathway. The strategic intent behind the creation of COMMD8 inhibitors is to precisely intervene in the molecular activities of this protein, potentially leading to orchestrated perturbations in the cellular mechanisms under its jurisdiction. The meticulous development of COMMD8 inhibitors necessitates an exhaustive comprehension of the protein's intricate structural attributes and its complex network of interacting partners. This understanding is harnessed to discern small molecular entities that can exclusively bind to COMMD8, subsequently inducing a controlled deviation from its normative operational capacity. These inhibitors undergo rigorous scrutiny to ensure their selectivity and effectiveness in specifically targeting COMMD8, thereby avoiding unintended impacts on unrelated cellular components. The overarching objective behind the exploration of COMMD8 inhibitors transcends the confines of standard cellular manipulation. Instead, it serves as a pioneering endeavor to unravel the underlying mechanisms that govern cellular regulation and intricate signaling pathways. By delving into the intricacies of COMMD8's involvement in diverse physiological contexts, the study of these inhibitors has the potential to unearth unprecedented insights into the fundamental principles that underpin cellular functionality. As the investigation into COMMD8 inhibitors burgeons, it may unravel uncharted avenues for manipulating cellular processes intrinsically associated with COMMD8. This, in turn, could culminate in groundbreaking discoveries, ultimately broadening our horizons regarding the underpinnings of cellular biology and advancing our comprehension of the intricate dance of molecular interactions that orchestrate fundamental biological phenomena.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dinaciclib

779353-01-4sc-364483
sc-364483A
5 mg
25 mg
$247.00
$888.00
1
(0)

Dinaciclib is a multi-CDK inhibitor with activity against CDK1, CDK2, CDK5, and CDKIt's being investigated for various types of cancers, including hematologic malignancies and solid tumors.

Flavopiridol

146426-40-6sc-202157
sc-202157A
5 mg
25 mg
$78.00
$259.00
41
(3)

Flavopiridol is a pan-CDK inhibitor targeting CDK1, CDK2, CDK4, CDK6, CDK7, and CDKIt has been studied in research models for several types of cancers.

Roscovitine

186692-46-6sc-24002
sc-24002A
1 mg
5 mg
$94.00
$265.00
42
(2)

Roscovitine is a pan-CDK inhibitor that has been studied to inhibit CDK1, CDK2, CDK5, and CDK7.

SNS-032

345627-80-7sc-364621
sc-364621A
5 mg
10 mg
$169.00
$262.00
(1)

SNS-032 is a CDK2, CDK7, and CDK9 inhibitor. It has been explored for its anticancer activity in both solid tumors and hematologic malignancies.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

LEE011, also known as Ribociclib (different from the Ribociclib mentioned earlier), is a selective CDK4/6 inhibitor.

P276-00

920113-03-7sc-477932
1 mg
$380.00
(0)

P276-00 is a novel CDK inhibitor with activity against CDK1, CDK2, CDK4, and CDKIt has shown potential in research studies against various cancers.

AT7519

844442-38-2sc-364416
sc-364416A
sc-364416B
sc-364416C
5 mg
10 mg
100 mg
1 g
$291.00
$341.00
$1046.00
$3126.00
1
(0)

AT7519 is a multi-CDK inhibitor that targets CDK1, CDK2, CDK4, CDK6, CDK7, and CDKIt.